(redirected from orexigen)
Also found in: Medical.


a. orexígeno-a, que estimula el apetito.
References in periodicals archive ?
Orexigen (OREX) downgraded to Underperform from Market Perform at Wells Fargo with analyst Jim Birchenough citing the company's pending Chapter 11 bankruptcy and restructuring.
From 2007 to 2015, she served as general counsel and secretary at Orexigen Therapeutics, Inc.
From 2007 to 2015, she served as General Counsel and Secretary at Orexigen Therapeutics Inc, where she led various general and administrative functions including compliance, risk management, legal, human resources and facilities.
The Court's positive decision allows Orexigen to continue to fulfill its mission to provide innovative medicine to treat patients who are overweight or struggling with obesity.
At the closing, Orexigen will pay Takeda USD 60m to acquire Contrave US rights.
and Orexigen Therapeutics received approval from the FDA for Contrave (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/ m2 or greater in the presence of at least one weight-related comorbid condition.
The drug, called Contrave, was developed by Orexigen Therapeutics, a small company based in San Diego, and will be marketed by Takeda Pharmaceutical of Japan.
The top after-market Nasdaq losers were Nanosphere Inc, Orexigen Therapeutics Inc, Fulton Financial Corporation and Acme Packet Inc.
BANKING AND CREDIT NEWS-December 15, 2011--Leerink Swann to help Orexigen with units placement(C)2011 M2 COMMUNICATIONS http://www.
This month, the California firm Orexigen Therapeutics, which developed naltrexone/bupropion (Contrave) along with Takeda Pharmaceutical of Japan, announced that it had received a letter from the agency saying that the drug would not be approved in advance of "a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with naltrexone/bupropion does not adversely affect the drug's benefit-risk profile.
In other news, shares of Orexigen Therapeutics Inc.
Orexigen submitted a New Drug Application to the Food and Drug Administration for Contrave on March 31, and the Prescription Drug User Fee Act action date has been set for January 31, 2011.